Suhail Rasool is the Director of Neurodegenerative Diseases Research division at Truebinding Inc. His work involves developing diagnostic biomarkers and therapeutic modalities for AD and other neurodegenerative diseases. His major contributions from the past five years include: in vivo and ex vivo characterization of molecular probes and aggregates of various amyloid proteins for the diagnosis of AD, Parkinson’s disease, prion disease and cerebral amyloid angiopathy; in vivo and ex vivo characterization of molecular probes and aggregates of various amyloid proteins for the diagnosis of Traumatic brain injury (TBI) using the retina as a window; preclinical work for a novel Alzheimer’s disease diagnostic candidate; and investigation of fluorescent probes capable of labeling and enhancing visualization of amyloids in the retina. In late 2021, U.S. Food and Drug Administration (FDA) has granted clearance of the Investigational New Drug (IND) application to proceed with the clinical development of its lead product candidate, TB006, for the treatment of Alzheimer’s Disease.
Acceptance Letter
